^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    trastuzumab pamirtecan (BNT323)

    i
    Company:
    BioNTech, DualityBio
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (NCT06018337)
    Phase 3
    DualityBio Inc.
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/18/2024
    Primary completion :
    12/01/2025
    Completion :
    05/01/2028
    HER-2 • PGR
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive
    |
    capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (DB-1303-O-1001) (NCT05150691)
    Phase 1/2
    DualityBio Inc.
    Recruiting
    Last update posted :
    10/03/2024
    Initiation :
    01/31/2022
    Primary completion :
    04/01/2026
    Completion :
    10/01/2027
    HER-2
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Perjeta (pertuzumab) • trastuzumab pamirtecan (BNT323) • itraconazole • ritonavir